ASP-2138 is under clinical development by Xencor and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase I drugs for Adenocarcinoma Of The Gastroesophageal Junction have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ASP-2138’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ASP-2138 overview
ASP-2138 is under development for the treatment of adenocarcinoma of the gastroesophageal junction, metastatic pancreatic adenocarcinoma and gastric cancer. The therapeutic candidate is a bispecific antibody targeting CD3 and claudin 18.2 (CLDN18.2). It is administered through intravenous drip route. The drug candidate is being developed based on XmAb technology.
See Also:
Xencor overview
Xencor (Xencor) is a clinical-stage biopharmaceutical company that discovers and develops engineered monoclonal antibodies and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company product pipeline includes Vudalimab (PD1 x CTLA4), Plamotamab (CD20 x CD3), XmAb819 (ENPP3 x CD3), XmAb564 (IL-2-Fc) and XmAb104 (PD1 x ICOS). Its other pipeline includes XmAb306/RO7310729, XmAb968 and XmAb662 (IL12-Fc), among others. Xencor‘s Vudalimab is a bispecific antibody that simultaneously targets immune checkpoint receptors PD-1 and CTLA-4 and is designed to promote tumor-selective T-cell activation. Xencor is headquartered in Monrovia, California, the US.
For a complete picture of ASP-2138’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.